cis-Urocanic acid induces mast cell degranulation and release of preformed TNF-α: A possible mechanism linking UVB and cis-urocanic acid to immunosuppression of contact hypersensitivity

Skin Pharmacology and Applied Skin Physiology

Volumn 12, Issue 1-2, 1999, Pages 18-27

  Wille, John J ^a,c   Kydonieus, Agis F ^a   Murphy, George F ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Bioderm Technologies Inc   (United States)

Author keywords

cis urocanic acid; Contact dermatitis; Mast cell degranulation; Skin sensitization; Transdermal drugs

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; CAPSAICIN; CHLOROQUINE; CHYMASE; CROMOGLYCATE DISODIUM; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; TUMOR NECROSIS FACTOR ALPHA; UROCANIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTACT ALLERGY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; MAST CELL DEGRANULATION; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CULTURE; TOPICAL DRUG ADMINISTRATION; ULTRAVIOLET B RADIATION; VASCULAR ENDOTHELIUM;

ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHYMASES; CROMOLYN SODIUM; DERMATITIS, CONTACT; DIFFUSION; DRUG INTERACTIONS; E-SELECTIN; HUMANS; IMMUNOSUPPRESSION; INFANT, NEWBORN; MAST CELLS; MICE; MICE, INBRED BALB C; ORGAN CULTURE TECHNIQUES; SERINE ENDOPEPTIDASES; SKIN PHYSIOLOGY; TUMOR NECROSIS FACTOR-ALPHA; ULTRAVIOLET RAYS; UROCANIC ACID;

EID: 0032997085     PISSN: 14222868     EISSN: None     Source Type: Journal    
DOI: 10.1159/000029842     Document Type: Article

References (32)

1. Fischer AA: Contact dermatitis from topical medicaments. Semin Dermatol 1982;1:49-57.
2. Maibach HI: Clonidine: Irritant and contact dermatitis assays. Contact Dermatitis 1985;12:192-196.
3. Rietschel RL, Fowler JE Jr (eds): Fisher's Contact Dermatitis, ed 4. Baltimore, Williams & Wilkins, 1995.
4. Diezel W, Gruner S, Diaz LA, Anhalt GJ: Inhibition of cutaneous contact hypersensitivity by calcium transport inhibitors lanthanum and diltiazem. J Invest Dermatol 1989; 93:322-326.
5. Amkraut A, Jordan W, Taskovich L: Effect of co-administration of corticosteroids on the development of contact sensitization. J Am Acad Dermatol 1996;35:27-31.
6. McFadden J, Bacon K, Camp R: Topically applied verapamil hydrochloride inhibits tuberculin-induced delayed-type hypersensitivity reactions in human skin. J Invest Dermatol 1992;99:784-786.
7. Gallo RL, Granstein RD: Inhibition of allergic contact dermatitis and ultraviolet irradiation-induced tissue swelling in the mouse by amiloride. Arch Dermatol 1989;125:502-506.
8. Kalish RS, Wood JA, Kydonieus A, Wille JJ: Prevention of contact hypersensitivity to topically applied drugs by ethacrynic acid: Potential application to transdermal drug delivery. J Control Rel 1997;48:79-87.
9. DeFabo E, Noonan F: Mechanism of immune suppression by ultraviolet light in vivo. J Exp Med 1983; 157:84-98.
10. Streilein JW: cis-Urocanic acid induces immune tolerance. J Invest Dermatol 1993;105:76.
11. Kurimoto I, Streilein JW: cis-Urocanic acid suppression of contact hypersensitivity induction is mediated via tumor necrosis factor-α. J Invest Dermatol 1992;148:3072-3078.
12. Lavker RM, Kaminer MS, Murphy GF: Mast cell degranulation results in endothelial activation after acute exposure of human skin to UV irradiation; in Marks R, Plewig G (eds): Environmental Threat to the Skin. London, Dunitz, 1992, pp 125-129.
13. Walsh LJ, Trinchieri G, Waldorf HA, Whitaker D, Murphy GF: Human dermal mast cells contain and release tumor necrosis factor-α which induces endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci USA 1991;88:4220-4224.
14. Klein LM, Lavker RM, Matis WL, Murphy GF: Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. Proc Natl Acad Sci USA 1989;86:8972-8976.
15. Laerma AI, Maibach HI: Topical cis-urocanic acid suppresses both induction and elicitation of contact hypersensitivity in Balb/c mice. Acta Derm Venereol (Stockh) 1995; 77:272-275.
16. Yarosh DB, Alas L, Kibitel AL, Ullrich SE: Urocanic acid, immunosuppressive cytokines, and the induction of human immunodeficiency virus. Photodermatol Photoimmunol Photomed 1992;9:127-135.
17. Moodycliffe AM, Kimber I, Norval M: The effect of ultraviolet B irriadiation and urocanic acid isomer on dendritic cell migration. Immunology 1992;77:394-399.
18. Kurimoto I, Streilein JW: Deleterious effects of cis-urocanic acid and UVB radiation on Langerhans cells and on the induction of contact hypersensitivity are mediated by tumor necrosis factor-α. J Invest Dermatol 1992;99:69s-70s.
19. Moodycliffe AM, Bucana CD, Kripke ML, Norval M, Ullrich SE: Differential effects of a monoclonal antibody to cis-urocanic acid on the suppression of delayed and contact hypersensitivity following ultraviolet irradiation. J Immunol 1996; 157:2891-2899.
20. El-Ghorr AA, Norval M: A monoclonal antibody to cis-urocanic acid prevents the UV-induced changes in Langerhans cells and DTH responses in mice, although not preventing dendritic cell accumulation in lymph nodes draining the site of irradiation and contact hypersensitivity responses. J Invest Dermatol 1994;105:264-269.
21. Wille JJ, Njieha F, Amin P, Kydonieus A: Topical delivery of mast cell degranulating agents for treatment of transdermal drug-induced hypersensitivity. Proc Int Symp Cotrol Rel Bioact Mater 1995;22:119-120.
22. Shaw JE, Prevo ME, Amkraut AA: Testing of controlled release transdermal dosage forms. Arch Dermatol 1987;123:1548-1556.
23. Kaminer MS, Lavker RM, Walsh LJ, Whitaker D, Ziverman B, Murphy GF: Extracellular localization of human connective tissue mast cell granule contents. J Invest Dermatol 1991;96:1-8.
24. Green KB, Lim HW: Effects of chloroquine on release of mediators from mast cells. Skin Pharmacol 1989;2:77-85.
25. Maurer M, Paus R, Galli SJ: Capsaicin-induced cutaneous inflammation in mast cell-deficient mice. J Invest Dermatol 1993;101:722.
26. Shimizu M, Streilein JW: Transepidermal induction of contract hypersensitivity in mice with a water-soluble antigen. J Invest Dermatol 1993; 101:749-753.
27. Yamazaki S, Yokezeki H, Sahoh T, Katayama I, Nishioka K: TNF-α, RANTES, and MCP 1 are major chemoattractants of murine Langerhans cells to the regional lymph nodes. Exp Dermatol 1998;7:35-41.
28. Jakob T, Udey MC: Regulation of E-cadherin-mediated adhesion in Langerhans cell-like dendritic cells by inflammatory mediators that mobilize Langerhans cell in vivo. J Immunol 1998;160:4067-4073.
29. Cumberbatch M, Dearman RJ, Kimber I: Langerhans cells require signals from both tumor necrosis factor-alpha and interleukin-1 beta for migration. Immunology 1997; 92:388-395.
30. Price AA, Cumberbatch M, Kimber I, Ager A: Alpha 6 integrins are required for Langerhans cell migration from the epidermis. J Exp Med 1997;186:1725-1735.
31. Ioffreda MD, Whitaker D, Murphy GF: Mast cell degranulation upregulates α6 integrins on epidermal Langerhans cells. J Invest Dermatol 1993;101:150-154.
32. Lambert RW, Granstein RD: Neuropeptides and Langerhans cells. Exp Dermatol 1998;7:73-80.